The two companies will work in tandem to provide customers worldwide with access to genes up to 70 kilobases in length.
The collection will be made available by BioBricks at no cost to the research community.
Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology.
Through the deal, Ginkgo has picked up Gen9's manufacturing platform and suite of proprietary technologies, software, and informatics tools for DNA synthesis and assembly.
The company intends to use the proceeds of the round to advance its proprietary enzymatic DNA synthesis technology called EcoDNA.
The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.
The DNA foundries have been funded through an £18 million ($23.5 million) investment from the BBSRC and should all be fully operational by next year.
Gen9's arrangement with renewable products firm Amyris comes about two months after it launched an access program for its low-cost DNA synthesis services.
Seattle-based chemical manufacturer Arzeda will buy megabase quantities of synthetic DNA from Gen9 for use in developing new advanced molecules.
The Cambridge, Massachusetts-based DNA manufacturer is looking to max out its production capacity, which works best at high volume and throughput.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.